(RTTNews) - Alnylam Pharmaceuticals, Inc. (ALNY) on Friday reported its investigational drug Brezosiran, previously known as ALN-HTT02, reduced mutant huntingtin protein levels in initial Phase 1b trial in Huntington's disease.